Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17401106 | 1.00 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17401143 | 1.00 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17397274 | 0.94 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17401161 | 0.94 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17401166 | 0.93 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17397166 | 0.93 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17397305 | 0.92 | PIK3CA (0.67) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17401187 | 0.92 | PIK3CA (0.67) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17401178 | 0.90 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17401164 | 0.90 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | claimed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | claimed |
| EP-3164400-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | Lupin Limited (IN) | 2017-05-10 | — | — | EP | claimed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-3164400-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | Lupin Limited (IN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | PIK3CD 5/4885PIK3CA 4/4885PIK3CB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.